Erythrocytosis associated with <i>EPAS1</i>(<i>HIF2A</i>), <i>EGLN1</i>(<i>PHD2</i>), <i>VHL, EPOR</i> or <i>BPGM</i> mutations: The Mayo Clinic experience

• Naseema Gangat,
• Jennifer L. Oliveira,
• Tavanna R Porter,
• James D. Hoyer,
• Aref Al-Kali,
• Mrinal M. Patnaik,
• Animesh Pardanani,
• Ayalew Tefferi

Affiliations

Naseema Gangat

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN

Jennifer L. Oliveira

Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN

Tavanna R Porter

Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN

James D. Hoyer

Division of Hematopathology, Department of Laboratory Medicine, Mayo Clinic, Rochester, MN

Aref Al-Kali

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN

Mrinal M. Patnaik

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN

Animesh Pardanani

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN

Ayalew Tefferi

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN